FDA Approves METHYLPHENIDATE HYDROCHLORIDE — Amneal Pharmaceuticals of New York LLC

Amneal Pharmaceuticals has secured FDA approval for methylphenidate hydrochloride, the generic version of the widely prescribed attention-deficit hyperactivity disorder treatment. The green light for oral administration in ANDA 205105 suggests Amneal is poised to capitalize on sustained demand in the stimulant market.